



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
| 10/666,752      | 09/18/2003  | Tran Thong           | 117163-2            | 8009             |

21324 7590 09/11/2006

HAHN LOESER & PARKS, LLP  
One GOJO Plaza  
Suite 300  
AKRON, OH 44311-1076

EXAMINER

REIDEL, JESSICA L

ART UNIT

PAPER NUMBER

3766

DATE MAILED: 09/11/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

10/666,752

Applicant(s)

THONG ET AL.

Examiner

Jessica L. Reidel

Art Unit

3766

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 12 July 2006.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-15 and 27-32 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-15 and 27-32 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 12 July 2006 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)                     | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____                                      |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)          | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date. _____   | 6) <input type="checkbox"/> Other: _____                          |

### **DETAILED ACTION**

1. Acknowledgement is made of Applicant's Amendment, which was received by the Office on July 12, 2006. Claims 16-26 and 33-42 have been cancelled. Claims 1-15 and 27-32 are pending.

#### ***Drawings***

2. In view of the response filed on July 12, 2006, the objections made to the drawings in the Office Action of April 18, 2006 have been withdrawn.

#### ***Specification***

3. In view of the response filed on July 12, 2006, the objections made to the specification in the Office Action of April 18, 2006 have been withdrawn.

#### ***Claim Objections***

4. In view of the response filed on July 12, 2006, the objections made to the claims in the Office Action of April 18, 2006 have been withdrawn.

#### ***Claim Rejections - 35 USC § 112***

5. In view of the response filed on July 12, 2006, the 35 U.S.C. 112 rejections made in the Office Action of April 18, 2006 have been withdrawn.

***Claim Rejections - 35 USC § 102***

6. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

7. Claims 1-15 and 27-32 are rejected under 35 U.S.C. 102(b) as being anticipated by Starkweather (U.S. 5,836,971). As to Claim 1, Starkweather discloses an implantable cardioverter/defibrillator/pacemaker (ICD), read as an arrangement 20 for treatment of rhythm disturbances, especially tachycardia and fibrillation of a heart 28 (see Starkweather Fig. 1, Abstract and column 1, lines 7-16 and 32-39) comprising a sense amplifier 42 coupled to a control/timing circuit 22, collectively read as a device for detecting the heart rhythm (i.e. the time that elapses between consecutive R-waves and/or P-waves) and determining when the lower limit of a fibrillation rate zone is exceeded, read as determining when a fibrillation threshold limit is exceeded, where the fibrillation threshold limit corresponds to a first predetermined heart rate value (see (Starkweather Fig. 3, column 7, lines 43-59, column 8, lines 22-42 and column 9, lines 3-44). The arrangement 20 of Starkweather further comprises a high voltage generator 26 and pulse generator 24, collectively read as a therapy delivery device, connected to the heart rhythm detecting device (sense amplifier 42 and control/timing circuit 22) to begin to treat a fibrillation episode when the fibrillation threshold limit is exceeded (see Starkweather Fig. 1, column 7, lines 20-22, column 9, lines 55-67, column 10, lines 1-5, column 13, lines 64-67 and column 14, lines 1-4).

Starkweather further discloses that the fibrillation threshold limit is lowered, i.e. a rate zone below the current rate zone the heart rhythm has been classified into is “pulled up” into the current rate zone for redetection purposes to ensure that the patient will receive optimal therapy upon subsequent arrhythmia redetections, i.e. the therapy delivery device continues to treat the same arrhythmia episode as long as the heart rhythm detecting device determines that the heart rate still exceeds the now “pulled up” lower limit of the rate zone, read as a redetection threshold limit (see Starkweather column 9, lines 45-67, column 10, lines 1-23, column 11, lines 60-67 and column 14, lines 1-47). Starkweather specifies at column 6, lines 52-60 that

Typically, an arrhythmia is considered to be a rapid irregular rhythm of the heart, e.g., ventricular tachycardia or ventricular fibrillation. However, for purposes of the present application the term arrhythmia also includes atrial tachycardia, atrial fibrillation, and asystole (a stopped heart). Thus, as used herein, the term “arrhythmia” is used broadly to indicate any irregular rhythm of the heart that interferes with the heart's ability to perform its basic function as a pump.

Starkweather also discloses that there are the following rate zones for the detected arrhythmias: fibrillation, high rate tachycardia and low rate tachycardia (see Starkweather Fig. 3). Starkweather expressly discloses the process for detection, treatment and redetection of a high rate ventricular tachycardia (VT) and generally discloses the process carried out by the arrangement 20 for detection, treatment and redetection of an arrhythmia in the other rate zones (i.e. low rate tachycardia or fibrillation). Although Starkweather does not expressly disclose the method for when the detected arrhythmia falls into the other rate zones disclosed, it is inherent that when the detected arrhythmia is a fibrillation, by default a synonymous method would occur upon detection of an arrhythmia in the fibrillation rate zone meaning (again by default) that a fibrillation is detected when the detected heart rate exceeds a fibrillation threshold limit of approximately 240 bpm. After delivering of defibrillation shocks, the redetected heart rhythm is

Art Unit: 3766

then compared to a redetection threshold limit of 200 bpm (the “pulled up” lower limit of the high rate VT rate zone into the current rate zone) and the therapy delivery device continues to treat the same fibrillation episode if the detected heart rhythm exceeds 200 bpm (i.e. the redetection threshold limit which is lower than the fibrillation threshold limit of 240 bpm and higher than a tachycardia threshold limit of approximately 150 bpm (see Starkweather Figs. 3 and 4A-4D, column 9, lines 45-67, column 10, lines 1-23, column 11, lines 60-67 and column 14, lines 1-47)).

8. As to Claim 2, Starkweather discloses that the therapy deliver device delivers a series of electrical impulses to the heart 28 via electrodes 32, 38 and 40 (see Starkweather column 7, lines 20-32, column 9, lines 45-67, column 10, lines 1-23, column 11, lines 60-67 and column 14, lines 1-47).

9. As to Claims 3 and 4, Starkweather discloses that the heart rhythm detector (sense amplifier 42 and control/timing circuit 22) may detect an atrial fibrillation (see Starkweather column 6, lines 52-65, column 7, lines 43-59, column 8, lines 37-67 and column 9, lines 1-14) and that the therapy device may treat the atrial fibrillation (see Starkweather column 7, lines 1-19).

10. As to Claim 5, Starkweather discloses that the heart rhythm detector (sense amplifier 42 and control/timing circuit 22) may comprise an electrode 32 that may be situated in a region of an atrium of the heart 28 to detect the electrical activity thereof and that the therapy device including a pulse generator 24 and high voltage generator 26 may be connected to electrode 32 to deliver electrical pulses (an anti-tachycardia pacing regimen for example) to the atrium (see Starkweather column 7, lines 1-19).

Art Unit: 3766

11. As to Claims 6-10, Starkweather discloses that the heart rhythm detector (sense amplifier 42 and control/timing circuit 22) may detect a ventricular fibrillation that the therapy device may treat the ventricular fibrillation (see Starkweather column 6, lines 52-65, column 7, lines 43-59, column 8, lines 37-67 and column 9, lines 1-14).

12. As to Claims 11-15, Starkweather discloses that the heart rhythm detector (sense amplifier 42 and control/timing circuit 22) may comprise an electrode 32 that may be situated in a region of a ventricle of the heart 28 to detect the electrical activity thereof and that the therapy device including a pulse generator 24 and high voltage generator 26 may be connected to electrodes 32, 38 and 40 to deliver anti-tachycardia pacing pulses/cardioversion/defibrillation therapy (see Starkweather column 7, lines 1-42).

13. As to Claims 27-30, Starkweather discloses that the heart rhythm detector (sense amplifier 42 and control/timing circuit 22) may determine when a tachycardia is occurring and the therapy device begins to treat the tachycardia when the tachycardia is detected, i.e. the detected heart rhythm is less than the lower limit for a high rate tachycardia but greater than the lower limit for a low rate tachycardia and pulse generator 24 emits an anti-tachycardia pacing regimen or the detected heart rhythm is less than the lower limit for fibrillation but greater than the lower limit for high rate tachycardia and the therapy delivery device delivers a first programmed shock for the VT high rate zone (see Starkweather Fig. 3 column 7, lines 20-32, column 9, lines 45-67, column 10, lines 1-23, column 11, lines 60-67 and column 14, lines 1-47).

14. As to Claims 31-32, Starkweather discloses that “pulling up” all lower rate zones into the corresponding rate zone permits the arrangement 20 to ensure that all subsequent arrhythmia redetection in a lower rate zone does not result in the delivery of a lower tier of therapy, e.g. a

Art Unit: 3766

lower energy shock than the last tier of therapy delivered (see Starkweather column 13, lines 64-67 and column 14, lines 1-23). By default, the arrangement 20 of Starkweather is designed so that no tachycardia treatment (i.e. cardioversion shocks) is performed during a fibrillation treatment (i.e. high energy defibrillation shocks).

### *Response to Arguments*

15. Applicant's arguments filed July 12, 2006 have been fully considered but they are not persuasive. In response to Applicant's argument that "Starkweather does not teach or suggest a heart rhythm detecting device determining whether a redetection threshold limit, corresponding to a second predetermined heart rate value, is still exceeded immediately after the therapy device has treated the fibrillation episode, the redetection threshold limit being lower than the fibrillation threshold limit and higher than a tachycardia threshold limit which corresponds to a third predetermined heart rate value" (see page 11 of the Remarks), the Examiner respectfully disagrees. As discussed above, the Examiner has noted that Starkweather *expressly discloses* the process for detection, treatment and redetection of a high rate ventricular tachycardia (VT) [emphasis added]. Starkweather, however, does *generally disclose* the process carried out by the arrangement 20 for detection, treatment and redetection of an arrhythmia in the other rate zones (see Starkweather Fig. 3, column 6, lines 52-67 and columns 7-14) [emphasis added]. Although Starkweather does not expressly disclose the method for when the detected arrhythmia falls into the other rate zones disclosed it is inherent that when the detected arrhythmia is a fibrillation, by default a synonymous method would occur upon detection of an arrhythmia in the fibrillation rate zone.



***Conclusion***

16. The prior art made of record and not relied upon is considered pertinent to Applicant's disclosure.

17. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).


A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.


18. Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Jessica L. Reidel whose telephone number is (571) 272-2129. The Examiner can normally be reached on Mon-Thurs 8:00-5:30, every other Fri 8:00-4:30.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Robert Pezzuto can be reached on (571) 272-6996. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 3766

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

  
Jessica L. Reidel  
Examiner  
Art Unit 3766  
09/01/06

  
Robert E. Pezzuto  
Supervisory Patent Examiner  
Art Unit 3766